>
Switch to:

Illumina Net Income From Continuing Operations

: $701 Mil (TTM As of Mar. 2022)
View and export this data going back to 2000. Start your Free Trial

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Illumina's net income from continuing operations for the three months ended in Mar. 2022 was $86 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2022 was $701 Mil.

Illumina Net Income From Continuing Operations Historical Data

The historical data trend for Illumina's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Income From Continuing Operations
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 678.00 782.00 990.00 656.00 762.00

Illumina Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Net Income From Continuing Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.00 186.00 317.00 112.00 86.00

Illumina Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $701 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Business Description

Illumina logo
Industry
Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071
Comparable Companies
XSWX:LONN SHSE:603259 NYSE:IQV NAS:IDXX NYSE:A NYSE:MTD NYSE:LH NYSE:PKI XPAR:ERF NAS:ICLR
Traded in Other Exchanges
ILMN:Mexico 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany I1LM34:Brazil ILMN:Austria
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Website
https://www.illumina.com
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
Flatley Jay T director 9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H officer: SVP Product Development 5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles officer: SVP & General Counsel 5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A director, officer: President and CEO 350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark officer: SVP Chief Commercial Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P officer: SVP, Global Quality & Ops PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K officer: VP, Chief Accounting Officer INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L officer: SVP, Chief People Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa officer: SVP, Entrepreneurial Devlopmt 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E director 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell director C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

From GuruFocus

Gretel and Illumina Partner to Develop Synthetic Data for Genomic Research

By Business Wire 12-14-2021

Red-Hot Genomics Plays With Google-Like Dominance

By 12-17-2021

GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test

By Business Wire 12-06-2021

Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China

By PRNewswire 11-17-2021

Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test

By Business Wire 01-10-2022

Financial Consulate, Inc Buys iShares J.P. Morgan EM Corporate Bond ETF, Exxon Mobil Corp, Royalty Pharma PLC, Sells Invesco S&P 500 Equal Weight Financials ETF, Vanguard S&P 500 ETF, CrowdStrike Holdings Inc

By insider 02-07-2022

Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe

By PRNewswire 03-15-2022

Telos Capital Management, Inc. Buys Illumina Inc, United Parcel Service Inc, Newell Brands Inc, Sells Activision Blizzard Inc, iShares Biotechnology ETF, Merck Inc

By insider 01-21-2022

Illumina collaborates with Nashville Biosciences to accelerate medicines development

By PRNewswire 01-10-2022

Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference

By PRNewswire 01-10-2022

Other Sources

Illumina (ILMN) Q4 Earnings Top Estimates, Gross Margin Up

By Zacks 2022-02-11

Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics

By Zacks 2022-01-07

4 Toxic Stocks to Eliminate From Your Portfolio Now

By Zacks 2021-12-27

$ILMN - Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Cowen Health Care Conference (Transcript).…

By Seekingalpha 2022-03-07

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

By Zacks 2022-02-10

Illumina (ILMN) was Upgraded to a Hold Rating at Credit Suisse

By tipranks.com 2022-03-02

These 2 Nasdaq Winners Are Lighting Up the Market Tuesday

By Fool 2022-01-11

$ILMN - Illumina, Inc. (ILMN) JPMorgan 40th Annual Healthcare Conference (Transcript). Illumina Inc Ilmn Jpmorgan 40th Annual Healthcare Conference Transcript

By Seekingalpha 2022-01-10

$ILMN - Illumina's (ILMN) CEO Francis deSouza on Q4 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2022-02-10

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

By Zacks 2022-01-13

Illumina (ILMN) Invests in Seven Additional Genomics Startups

By Zacks 2022-03-18

Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test

By Zacks 2022-02-16

What's the Outlook for Illumina?

By Fool 2022-01-23

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

By Zacks 2022-02-03

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

By Zacks 2021-12-15

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)